Literature DB >> 16611857

Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.

Naoki Ishiguro1, Kazuya Maeda, Wataru Kishimoto, Asami Saito, Akiko Harada, Thomas Ebner, Willy Roth, Takashi Igarashi, Yuichi Sugiyama.   

Abstract

Telmisartan, a nonpeptide angiotensin II receptor antagonist, is selectively distributed to liver. In the present study, we have characterized the contribution of organic anion transporting polypeptide (OATP) isoforms to the hepatic uptake of telmisartan by isolated rat hepatocytes, human cryopreserved hepatocytes, and human transporter-expressing cells. Because it is difficult to evaluate the transport activity of telmisartan because of its extensive adsorption to cells and culture materials, we performed the uptake study in the presence of human serum albumin. The saturable uptake of telmisartan into isolated rat hepatocytes took place in a Na(+)-independent manner and was inhibited by pravastatin, taurocholate, and digoxin, which are Oatp substrates and inhibitors, but not by organic cation, tetraethylammonium, indicating the involvement of Oatp isoforms in its uptake into rat hepatocytes. To identify which human OATP transporters are important for the hepatic uptake of telmisartan, the uptake assay was carried out using OATP1B1- and OATP1B3-expressing human embryonic kidney 293 cells and cryopreserved human hepatocytes. The uptake of telmisartan by OATP1B3-expressing cells was saturable (K(m) = 0.81 microM) and significantly higher than that by vector-transfected cells. In contrast, no significant uptake was observed in OATP1B1-expressing cells. We also observed the saturable uptake of telmisartan by human hepatocytes. Thirty micromolar estrone-3-sulfate, which can selectively inhibit OATP1B1-mediated uptake compared with OATP1B3, did not inhibit the uptake of telmisartan in human hepatocytes, whereas it could inhibit the uptake of estradiol 17beta-d-glucuronide mediated by OATP1B1. These results suggest that OATP1B3 is predominantly involved in the hepatic uptake of telmisartan in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611857     DOI: 10.1124/dmd.105.009175

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  33 in total

1.  Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-06-04       Impact factor: 3.922

2.  Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Authors:  Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 3.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

5.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

6.  Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography.

Authors:  Makoto Kataoka; Tadayuki Takashima; Tomotaka Shingaki; Yoshinobu Hashidzume; Yumiko Katayama; Yasuhiro Wada; Hiroyuki Oh; Yoshie Masaoka; Shinji Sakuma; Yuichi Sugiyama; Shinji Yamashita; Yasuyoshi Watanabe
Journal:  Pharm Res       Date:  2012-05-23       Impact factor: 4.200

Review 7.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 8.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 9.  Predictive Value of Microdose Pharmacokinetics.

Authors:  Merel van Nuland; Hilde Rosing; Alwin D R Huitema; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 10.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.